A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

Inclusion Criteria:

1. Histopathologically confirmed patients with extensive small cell lung cancer;
2. Karnofsky performance status ≥70;
3. At least one lesion that can measured by CT;
4. Expected to survive for at least 3 months;
5. Peripheral blood and liver and kidney function within the following allowable range (tested within 7 days before treatment);

   * White blood cell (WBC) ≥3.0×109/L or Neutrophils (ANC) ≥1.5×109/L;
   * Hemoglobin (HGB) ≥80 g/L；
   * Platelet (PLT) ≥100×109/L;
   * Liver transaminases（AST/ALT）\<3.0 times the normal range limit;
   * Total bilirubin（TBIL）\<1.5 times the normal range limit;
   * Creatinine（CREAT）\<1.5 times the normal range limit;
6. Patients of childbearing age (including female and male patients' partner) must take effective contraception methods;
7. Signed informed consent;
8. Known history of liver disease: Hepatitis B Virus (HBV) infection and Hepatitis B Virus DNA (HBV DNA ≥500 copies or ≥100 IU/ml); or Hepatitis C Virus (HCV) infection; or liver cirrhosis, etc.
9. Human immunodeficiency virus (HIV);
10. Subjects with difficulties in swallowing or known drug malabsorption; Those who meet each of the above criteria are included in the study.

Exclusion Criteria:

1. Other pathological types of tumor except for small cell lung cancer;
2. Patients with a history of severe allergies or allergies;
3. Pregnancy or breastfeeding women;
4. Patients who have previously participated in other clinical trials and have not yet terminated the trial;
5. Combined with other tumors at the time of initial diagnosis;
6. Patients who have previously participated in other clinical trials and have not yet terminated the trial;
7. Patients who have acute infection that difficult to control;
8. Drug abuse, substance abuse, chronic alcohol abuse, and AIDS patients. Those who meet any of the above criteria are not included in the study.